What are the recommended management steps for a typical primary Epstein‑Barr virus infection presenting as infectious mononucleosis in an otherwise healthy patient?

Management of Primary Epstein-Barr Virus Infection (Infectious Mononucleosis) in Healthy Patients

For typical infectious mononucleosis in an otherwise healthy patient, treatment is entirely supportive—no antiviral therapy or routine corticosteroids are indicated. 1, 2

Diagnostic Confirmation

Initial Laboratory Testing

• Order a complete blood count with differential looking for absolute lymphocytosis with ≥50% lymphocytes and ≥10% atypical lymphocytes, which are present in most cases. 3, 2
• Perform a rapid heterophile antibody test (Monospot) as the first-line serologic screen, which has 87% sensitivity and 91% specificity. 3, 2

Timing Considerations for Testing

• The heterophile test typically becomes positive between days 6-10 after symptom onset; false-negative results occur in approximately 10% of patients overall and are especially common in the first week of illness and in children younger than 10 years. 3
• If clinical suspicion remains high after an initial negative heterophile test obtained in the first week, repeat the test after 7-10 days or proceed directly to EBV-specific serology. 3

EBV-Specific Serologic Testing

When heterophile testing is negative but suspicion persists, order three antibodies together: 3

• IgM to viral capsid antigen (VCA)
• IgG to VCA
• Antibodies to Epstein-Barr nuclear antigen (EBNA)

Acute primary infection is confirmed by the presence of VCA IgM (with or without VCA IgG) and the absence of EBNA antibodies. 1, 3 The presence of EBNA antibodies indicates infection occurred more than 6 weeks prior and effectively rules out acute mononucleosis. 3

Differential Diagnosis Testing

If both heterophile and EBV testing are negative, consider testing for: 3

• Cytomegalovirus (CMV) infection
• HIV infection (particularly in adolescents)
• Toxoplasma gondii infection
• Adenovirus infection
• Streptococcal pharyngitis (which may coexist)

Treatment Approach

Supportive Care Only

Aciclovir therapy does not ameliorate the course of infectious mononucleosis in otherwise healthy individuals. 1 Antiviral agents including aciclovir, ganciclovir, and foscarnet have no proven role in established disease in immunocompetent patients. 1

Activity Restriction

Counsel patients to restrict vigorous physical activity and avoid contact sports for 3-8 weeks from symptom onset to reduce the risk of splenic rupture, which occurs in 0.1-0.5% of cases and is potentially life-threatening. 3, 4, 2 Current guidelines recommend no athletic activity for three weeks from onset of symptoms, with shared decision-making for return to activity timing. 2

Corticosteroid Use

Corticosteroids should be reserved only for specific complications, particularly airway obstruction. 1 Routine use of corticosteroids is not recommended for uncomplicated infectious mononucleosis. 2 Corticosteroids may have a role in hastening resolution of immune-mediated anemia and thrombocytopenia but should be used judiciously. 5

Critical Medication Avoidance

In patients with suspected EBV infection, amoxicillin must be avoided because it precipitates a severe rash in the presence of active EBV infection. 3

Monitoring for Complications

High-Risk Features Requiring Close Monitoring

Monitor patients closely if they have: 6

• Female gender
• Absence of tonsillopharyngitis
• White blood cell count ≤10,000/mm³
• AST ≥150 IU/L

These factors are associated with increased risk of complications including hematologic, hepatobiliary, central nervous system, and obstructive airway problems, which occur in approximately 20% of hospitalized patients. 6

Expected Laboratory Findings

• Liver function tests (AST, ALT) are elevated in roughly 90% of cases and can reinforce the diagnosis when heterophile testing is negative. 3, 6
• Mean fever duration is approximately 10 days. 6
• Fatigue may be profound but tends to resolve within three months. 4

Infection Control Measures

The main contagious period extends approximately 7-10 days from symptom onset. 7 During this time:

• Practice hand hygiene with soap and water. 7
• Avoid sharing personal items that may contain saliva, including towels, pillows, eating utensils, and drinking containers. 7
• Avoid close contact with others, particularly for healthcare workers and childcare providers. 7

Special Population Considerations

This guidance applies only to otherwise healthy patients. In immunocompromised patients (including those on thiopurines or other immunomodulators), management differs significantly: immunomodulator therapy should be reduced or discontinued if possible, and specialist consultation should be sought due to increased risk of lymphoproliferative disorders and severe disease. 1, 3